Specify a stock or a cryptocurrency in the search bar to get a summary
Genflow Biosciences plc
GENFFGenflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Address: 6 Heddon Street, London, United Kingdom, W1B 4BT
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GENFF
Dividend Analytics GENFF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GENFF
Stock Valuation GENFF
Financials GENFF
Results | 2019 | Dynamics |